BUPROPION HCL
11 Limited Use · 2 not a benefit
Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable
- Duloxetine (Cymbalta): general benefit, Not a benefit
- Mirtazapine (Remeron RD): general benefit, Not a benefit
- Trazodone (Desyrel): general benefit, Not a benefit
- Venlafaxine (Effexor XR): general benefit
- Vortioxetine (Trintellix): general benefit
- Desvenlafaxine (Pristiq): not a benefit
17 more in the class list below
Odan Bupropion SR · DIN 02275074 · 100mg · tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Odan Bupropion SR · DIN 02275074
Manufacturer: Odan Laboratories Ltd.; listing date 2006-08-24
Health Canada: Marketed since 2021-05-14 · brand ODAN BUPROPION SR · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 100 MG · company Odan laboratoriesltd · schedule Prescription
Odan Bupropion SR: Formulary list price $0.5260/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5260 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76058 · Verify on the e-Formulary ↗ (DIN 02275074)
Source record
DIN 02275074: Odan Bupropion SR
Raw flags: sec12=Y, sec3=Y
Item: 281604102; group id 453; item number 1130; lccId 00077; manufacturer id ODN
Source form: Tab; strength: 100mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5260; ministry $0.5260
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275074
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76058
Interchangeable products
Wellbutrin SR · DIN 02237824 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02275074
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Bupropion XL · DIN 02439654 · 150mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Act Bupropion XL · DIN 02439654
Manufacturer: Actavis Pharma Company; listing date 2016-07-28
Health Canada: Marketed since 2020-05-28 · brand TEVA-BUPROPION XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Teva canada limited · schedule Prescription
Act Bupropion XL: Formulary list price $0.1463/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1463 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92405 · Verify on the e-Formulary ↗ (DIN 02439654)
Source record
DIN 02439654: Act Bupropion XL
Raw flags: sec12=Y, sec3=Y
Item: 281604120; group id 453; item number 1128; lccId 00077; manufacturer id ACV
Source form: ER Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.1463; ministry $0.1463
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439654
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92405
Interchangeable products
Odan-Bupropion XL · DIN 02565838 · $0.1463
Taro-Bupropion XL · DIN 02475804 · $0.1463
Wellbutrin XL · DIN 02275090 · $0.1463
Shortage status: active shortage (reported 2026-04-22, estimated to end 2026-09-15, last updated 2026-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439654
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Odan-Bupropion XL · DIN 02565838 · 150mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Odan-Bupropion XL · DIN 02565838
Manufacturer: Odan Laboratories Ltd.; listing date 2026-08-31
Health Canada: Marketed since 2026-07-23 · brand ODAN-BUPROPION XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Odan laboratoriesltd · schedule Prescription
Odan-Bupropion XL: Formulary list price $0.1463/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1463 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106839 · Verify on the e-Formulary ↗ (DIN 02565838)
Source record
DIN 02565838: Odan-Bupropion XL
Raw flags: sec12=Y, sec3=Y
Item: 281604120; group id 453; item number 1128; lccId 00077; manufacturer id ODN
Source form: ER Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.1463; ministry $0.1463
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02565838
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106839
Interchangeable products
Act Bupropion XL · DIN 02439654 · $0.1463
Taro-Bupropion XL · DIN 02475804 · $0.1463
Wellbutrin XL · DIN 02275090 · $0.1463
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02565838
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Bupropion XL · DIN 02475804 · 150mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Bupropion XL · DIN 02475804
Manufacturer: Sun Pharma; listing date 2019-07-31
Health Canada: Marketed since 2021-02-18 · brand TARO-BUPROPION XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Sun pharma canada inc · schedule Prescription
Taro-Bupropion XL: Formulary list price $0.1463/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1463 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96647 · Verify on the e-Formulary ↗ (DIN 02475804)
Source record
DIN 02475804: Taro-Bupropion XL
Raw flags: sec12=Y, sec3=Y
Item: 281604120; group id 453; item number 1128; lccId 00077; manufacturer id SPC
Source form: ER Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.1463; ministry $0.1463
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475804
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96647
Interchangeable products
Act Bupropion XL · DIN 02439654 · $0.1463
Odan-Bupropion XL · DIN 02565838 · $0.1463
Wellbutrin XL · DIN 02275090 · $0.1463
Shortage status: resolved shortage (ended 2025-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475804
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Wellbutrin XL · DIN 02275090 · 150mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Wellbutrin XL · DIN 02275090
Manufacturer: Valeant Canada Ltd.; listing date 2007-11-10
Health Canada: Marketed since 2021-06-11 · brand WELLBUTRIN XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Bausch health, canada inc. · schedule Prescription
Ministry pays: $0.1463 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76060 · Verify on the e-Formulary ↗ (DIN 02275090)
Source record
DIN 02275090: Wellbutrin XL
Raw flags: sec12=Y, sec3=Y
Item: 281604120; group id 453; item number 1128; lccId 00077; manufacturer id VAL
Source form: ER Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6335; ministry $0.1463
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275090
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76060
Interchangeable products
Act Bupropion XL · DIN 02439654 · $0.1463
Odan-Bupropion XL · DIN 02565838 · $0.1463
Taro-Bupropion XL · DIN 02475804 · $0.1463
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02275090
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Zyban · DIN 02238441 · 150mg · extended release tablet
Limited Use — Reason for Use code 423 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 423 required
Write on scriptLU code 423 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 423
Reason for Use code 423
For smoking-cessation treatment in adults, in conjunction with smoking-cessation
counseling.
Network Note: Limited to 12 weeks (168 tablets) of reimbursement per 365 days per patient.
Coverage limit:
LU Authorization Period: 12 Weeks.
No interchangeable product listed in the Ontario extract
Zyban · DIN 02238441
Manufacturer: Valeant Canada Ltd.; listing date 2011-08-04
Health Canada: Marketed since 2021-06-04 · brand ZYBAN · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Bausch health, canada inc. · schedule Prescription
Zyban: Formulary list price $1.3541/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3541 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61860 · Verify on the e-Formulary ↗ (DIN 02238441)
Source record
DIN 02238441: Zyban
Raw flags: sec12=Y, sec3=Y
Item: 920000632; group id 901; item number 2160; lccId 00210; manufacturer id VAL
Source form: SR Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.3541; ministry $1.3541
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238441
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61860
Shortage status: resolved shortage (ended 2019-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238441
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Odan Bupropion SR · DIN 02275082 · 150mg · tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Odan Bupropion SR · DIN 02275082
Manufacturer: Odan Laboratories Ltd.; listing date 2006-08-24
Health Canada: Marketed since 2021-05-14 · brand ODAN BUPROPION SR · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Odan laboratoriesltd · schedule Prescription
Odan Bupropion SR: Formulary list price $0.9169/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9169 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76059 · Verify on the e-Formulary ↗ (DIN 02275082)
Source record
DIN 02275082: Odan Bupropion SR
Raw flags: sec12=Y, sec3=Y
Item: 281604103; group id 453; item number 1131; lccId 00077; manufacturer id ODN
Source form: Tab; strength: 150mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.9169; ministry $0.9169
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275082
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76059
Interchangeable products
Wellbutrin SR · DIN 02237825 · not recorded
Shortage status: resolved shortage (ended 2021-03-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02275082
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Bupropion XL · DIN 02439662 · 300mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Act Bupropion XL · DIN 02439662
Manufacturer: Actavis Pharma Company; listing date 2016-07-28
Health Canada: Marketed since 2020-05-28 · brand TEVA-BUPROPION XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 300 MG · company Teva canada limited · schedule Prescription
Act Bupropion XL: Formulary list price $0.2927/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2927 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92406 · Verify on the e-Formulary ↗ (DIN 02439662)
Source record
DIN 02439662: Act Bupropion XL
Raw flags: sec12=Y, sec3=Y
Item: 281604121; group id 453; item number 1129; lccId 00077; manufacturer id ACV
Source form: ER Tab; strength: 300mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2927; ministry $0.2927
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439662
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92406
Interchangeable products
Odan-Bupropion XL · DIN 02565846 · $0.2927
Taro-Bupropion XL · DIN 02475812 · $0.2927
Wellbutrin XL · DIN 02275104 · $0.2927
Shortage status: active shortage (reported 2026-04-22, estimated to end 2026-09-15, last updated 2026-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439662
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Odan-Bupropion XL · DIN 02565846 · 300mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Odan-Bupropion XL · DIN 02565846
Manufacturer: Odan Laboratories Ltd.; listing date 2026-08-31
Health Canada: Marketed since 2026-07-23 · brand ODAN-BUPROPION XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 300 MG · company Odan laboratoriesltd · schedule Prescription
Odan-Bupropion XL: Formulary list price $0.2927/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2927 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106840 · Verify on the e-Formulary ↗ (DIN 02565846)
Source record
DIN 02565846: Odan-Bupropion XL
Raw flags: sec12=Y, sec3=Y
Item: 281604121; group id 453; item number 1129; lccId 00077; manufacturer id ODN
Source form: ER Tab; strength: 300mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2927; ministry $0.2927
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02565846
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106840
Interchangeable products
Act Bupropion XL · DIN 02439662 · $0.2927
Taro-Bupropion XL · DIN 02475812 · $0.2927
Wellbutrin XL · DIN 02275104 · $0.2927
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02565846
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Bupropion XL · DIN 02475812 · 300mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Bupropion XL · DIN 02475812
Manufacturer: Sun Pharma; listing date 2019-07-31
Health Canada: Marketed since 2021-02-18 · brand TARO-BUPROPION XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 300 MG · company Sun pharma canada inc · schedule Prescription
Taro-Bupropion XL: Formulary list price $0.2927/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2927 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96648 · Verify on the e-Formulary ↗ (DIN 02475812)
Source record
DIN 02475812: Taro-Bupropion XL
Raw flags: sec12=Y, sec3=Y
Item: 281604121; group id 453; item number 1129; lccId 00077; manufacturer id SPC
Source form: ER Tab; strength: 300mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2927; ministry $0.2927
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475812
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96648
Interchangeable products
Act Bupropion XL · DIN 02439662 · $0.2927
Odan-Bupropion XL · DIN 02565846 · $0.2927
Wellbutrin XL · DIN 02275104 · $0.2927
Shortage status: resolved shortage (ended 2025-05-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475812
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Wellbutrin XL · DIN 02275104 · 300mg · extended release tablet
Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Wellbutrin XL · DIN 02275104
Manufacturer: Valeant Canada Ltd.; listing date 2007-11-10
Health Canada: Marketed since 2021-06-11 · brand WELLBUTRIN XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 300 MG · company Bausch health, canada inc. · schedule Prescription
Ministry pays: $0.2927 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76061 · Verify on the e-Formulary ↗ (DIN 02275104)
Source record
DIN 02275104: Wellbutrin XL
Raw flags: sec12=Y, sec3=Y
Item: 281604121; group id 453; item number 1129; lccId 00077; manufacturer id VAL
Source form: ER Tab; strength: 300mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.2674; ministry $0.2927
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275104
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76061
Interchangeable products
Act Bupropion XL · DIN 02439662 · $0.2927
Odan-Bupropion XL · DIN 02565846 · $0.2927
Taro-Bupropion XL · DIN 02475812 · $0.2927
Shortage status: resolved shortage (ended 2024-10-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02275104
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Wellbutrin SR · DIN 02237825 · 150mg · tablet
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Wellbutrin SR · DIN 02237825
Manufacturer: Valeant Canada Ltd.; listing date 2000-04-17
Health Canada: Dormant since 2021-03-10 · brand WELLBUTRIN SR · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Bausch health, canada inc. · schedule Prescription
Wellbutrin SR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61184 · Verify on the e-Formulary ↗ (DIN 02237825)
Source record
DIN 02237825: Wellbutrin SR
Raw flags: notABenefit=Y, sec3=Y
Item: 281604103; group id 453; item number 1131; lccId 00077; manufacturer id VAL
Source form: Tab; strength: 150mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237825
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61184
Interchangeable products
Odan Bupropion SR · DIN 02275082 · $0.9169
Shortage status: active shortage (reported 2019-02-01, last updated 2019-06-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237825
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-03-10 — choose a marketed DIN from the same-category list.
Wellbutrin SR · DIN 02237824 · 100mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.Discontinued 2008-11-14 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315
For the treatment of depression.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Wellbutrin SR · DIN 02237824
Manufacturer: Biovail Pharmaceuticals Canada; listing date 2000-04-17
Health Canada: Cancelled post market since 2008-11-14 · brand WELLBUTRIN SR · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 100 MG · company Biovail pharmaceuticals canada division of biovail corporation · schedule Prescription
Wellbutrin SR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61183 · Verify on the e-Formulary ↗ (DIN 02237824)
Source record
DIN 02237824: Wellbutrin SR
Raw flags: notABenefit=Y, sec3=Y
Item: 281604102; group id 453; item number 1130; lccId 00077; manufacturer id BIO
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237824
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61183
Interchangeable products
Odan Bupropion SR · DIN 02275074 · $0.5260
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237824
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered
Matched class: 28:16:04 Antidepressants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE
Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE
28:16:04 Antidepressants
· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap
· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab
· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab
· 45 products · General benefit · strengths: 37.5mg, 75mg, 150mg · ER Cap
· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab
· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab
· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab
· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab
· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab
· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab
· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04
and 12 more
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered
Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM
Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL
92:00 UNCLASSIFIED THERAPEUTIC AGENTS
· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab
· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab
· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab
· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L
· 3 products · General benefit · strengths: 50mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab
· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab
· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L
· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk
· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk
· 16 products · General benefit · strengths: 10mg, 20mg · Tab
· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00
and 75 more
Free programs for Smoking cessation (Ontario):
Ontario Drug Benefit (ODB) Plan coverage of Champix® and Zyban® — coverage of varenicline (Champix®) and bupropion (Zyban®); generic varenicline and bupropion are Limited Use (Reason for Use code 423 for varenicline: 'For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling', limited to 12 weeks, 168 tablets, per 365 days; code 315 for bupropion) — patients who are seniors (age 65+), in long term-care homes, or those on social assistance (welfare or because of disability) — not stated
(toronto.ca, Sep 9, 2026 ↗)
Implementing STOP (Smoking Treatment for Ontario Patients) — publicly funded Nicotine Replacement Therapy (NRT) for your patients — residents of Ontario — free
(intrepidlab.ca, Sep 9, 2026 ↗)
STOP on the Net — free nicotine replacement therapy (NRT) patches and gum/lozenges for 6 weeks of treatment mailed to you within 2 weeks of enrollment — 18 years of age or older and lives within Ontario — free
(intrepidlab.ca, Sep 9, 2026 ↗)
Smokers' Helpline — quit coach for free, confidential, one-to-one support — patients who want tobacco use cessation counseling/support — free
(toronto.ca, Sep 9, 2026 ↗)
Pharmacy Smoking Cessation Program — smoking cessation counseling from a pharmacist — eligible ODB recipients — not stated
(toronto.ca, Sep 9, 2026 ↗)
The Guidebook also includes information on the Pharmacy Smoking Cessation Program for Ontario Drug Benefit recipients who want to quit smoking as part of the Ontario Government’s support to quit smoking.
(ontario.ca, Updated August 24, 2023 ↗)